サマリー

市場分析とインサイト。腫瘍学における抗体の世界市場
2020年のオンコロジー用抗体の世界市場規模はXX百万米ドルで、2021年から2027年の間にXX％のCAGRで、2027年末までにXX百万米ドルに達すると予想されています。

オンコロジーにおける抗体の世界的な範囲と市場規模
オンコロジーにおける抗体市場は、企業別、地域（国）別、タイプ別、アプリケーション別に分類されています。世界のAntibodies in Oncology市場のプレイヤー、ステークホルダー、その他の参加者は、本レポートを強力なリソースとして活用することで、優位に立つことができるでしょう。セグメント別分析では、2016年から2027年までの市場規模と予測に焦点を当てています。
タイプ別セグメントでは、オンコロジーにおける抗体市場を、ミューリン抗体、キメラ・ヒト化抗体、完全ヒト化抗体、その他などに分類しています。
アプリケーション別では、腫瘍学における抗体市場は、病院、学術機関、診療所などに分類されます。

地域・国別分析
当レポートでは、米国、カナダ、ドイツ、フランス、英国、イタリア、ロシア、中国、日本、韓国、台湾、インド、オーストラリア、インドネシア、タイ、マレーシア、フィリピン、ベトナム、メキシコ、ブラジル、アルゼンチン、サウジアラビア、アラブ首長国連邦、トルコなど、さまざまな地域別・国別のAntibodies in Oncology市場を網羅的に評価しています。
本レポートでは、2016-2027年の期間において、北米、欧州、アジア太平洋、ラテンアメリカ、中東・アフリカの国（地域）別、タイプ別、アプリケーション別の市場規模、およびプレイヤー別の市場規模を掲載しています。

癌治療における抗体市場の競合状況とシェア分析
Antibodies in Oncology市場の競合状況は、ベンダーによる詳細やデータ情報を提供しています。2016年から2021年の期間、プレイヤーによる収益の包括的な分析と正確な統計を提供しています。また、2016年から2021年の期間におけるプレイヤー別の収益（世界および地域レベル）について、信頼性の高い統計に支えられた詳細な分析を提供しています。含まれる詳細は、会社概要、主要事業、会社の総収入とAntibodies in Oncology事業で得た収入、Antibodies in Oncology市場への参入日、Antibodies in Oncology製品の紹介、最近の開発状況などです。
主要ベンダーには、Novartis International AG、GlaxoSmithKline plc、Biogen Idec Inc.、Bristol Myers Squibb Co.、AstraZeneca plc.、Celltrion、3SBIO、Celgen Biopharma、Dr Reddy'sなどがあります。

ページTOPに戻る

目次

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Antibodies in Oncology Market Size by Type: 2016 VS 2021 VS 2027
1.2.2 Murine Antibodies
1.2.3 Chimeric and Humanised Antibodies
1.2.4 Fully Humanized Antibodies
1.2.5 Others
1.3 Market by Application
1.3.1 Global Antibodies in Oncology Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospitals
1.3.3 Academic Institutes
1.3.4 Clinics
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trend
2.1 Global Antibodies in Oncology Market Perspective (2016-2027)
2.2 Global Antibodies in Oncology Growth Trends by Regions
2.2.1 Antibodies in Oncology Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Antibodies in Oncology Historic Market Size by Regions (2016-2021)
2.2.3 Antibodies in Oncology Forecasted Market Size by Regions (2022-2027)
2.3 Industry Trends and Growth Strategy
2.3.1 Antibodies in Oncology Industry Trends
2.3.2 Antibodies in Oncology Market Drivers
2.3.3 Antibodies in Oncology Market Challenges
2.3.4 Antibodies in Oncology Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Antibodies in Oncology Players by Market Size
3.1.1 Players Covered: Ranking by Antibodies in Oncology Revenue
3.1.2 Global Top Antibodies in Oncology Players by Revenue (2016-2021)
3.1.3 Global Antibodies in Oncology Revenue Market Share by Players (2016-2021)
3.1.4 Global Antibodies in Oncology Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Antibodies in Oncology Market Concentration Ratio
3.2.1 Global Antibodies in Oncology Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 5 and Top 10 Players by Antibodies in Oncology Revenue in 2020
3.3 Antibodies in Oncology Key Players Head office and Area Served
3.4 Key Players Antibodies in Oncology Product Solution and Service
3.5 Date of Enter into Antibodies in Oncology Market
3.6 Mergers & Acquisitions, Expansion Plans

4 Global Antibodies in Oncology Breakdown Data by Type (2016-2027)
4.1 Global Antibodies in Oncology Historic Market Size by Type (2016-2021)
4.2 Global Antibodies in Oncology Forecasted Market Size by Type (2022-2027)

5 Global Antibodies in Oncology Breakdown Data by Application (2016-2027)
5.1 Global Antibodies in Oncology Historic Market Size by Application (2016-2021)
5.2 Antibodies in Oncology Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Antibodies in Oncology Market Size (2016-2027)
6.2 Key Antibodies in Oncology Players Market Share in North America (2020-2021)
6.3 North America Antibodies in Oncology Market Size by Country
6.3.1 North America Antibodies in Oncology Market Size by Country (2016-2021)
6.3.2 North America Antibodies in Oncology Market Size Forecast by Country (2022-2027)
6.4 U.S. Market Size Analysis
6.4.1 U.S. Antibodies in Oncology Market Size (2016-2027)
6.4.2 U.S. Antibodies in Oncology Market Size by Type (2016-2027)
6.4.3 U.S. Antibodies in Oncology Market Size by Application (2016-2027)
6.5 Canada Market Size Analysis
6.5.1 Canada Antibodies in Oncology Market Size (2016-2027)
6.5.2 Canada Antibodies in Oncology Market Size by Type (2016-2027)
6.5.3 Canada Antibodies in Oncology Market Size by Application (2016-2027)

7 Europe
7.1 Europe Antibodies in Oncology Market Size (2016-2027)
7.2 Key Antibodies in Oncology Players Market Share in Europe (2020-2021)
7.3 Europe Antibodies in Oncology Market Size by Country
7.3.1 Europe Antibodies in Oncology Market Size by Country (2016-2021)
7.3.2 Europe Antibodies in Oncology Market Size Forecast by Country (2022-2027)
7.4 Germany Market Size Analysis
7.4.1 Germany Antibodies in Oncology Market Size (2016-2027)
7.4.2 Germany Antibodies in Oncology Market Size by Type (2016-2027)
7.4.3 Germany Antibodies in Oncology Market Size by Application (2016-2027)
7.5 France Market Size Analysis
7.5.1 France Antibodies in Oncology Market Size (2016-2027)
7.5.2 France Antibodies in Oncology Market Size by Type (2016-2027)
7.5.3 France Antibodies in Oncology Market Size by Application (2016-2027)
7.6 U.K. Market Size Analysis
7.6.1 U.K. Antibodies in Oncology Market Size (2016-2027)
7.6.2 U.K. Antibodies in Oncology Market Size by Type (2016-2027)
7.6.3 U.K. Antibodies in Oncology Market Size by Application (2016-2027)
7.7 Italy Market Size Analysis
7.7.1 Italy Antibodies in Oncology Market Size (2016-2027)
7.7.2 Italy Antibodies in Oncology Market Size by Type (2016-2027)
7.7.3 Italy Antibodies in Oncology Market Size by Application (2016-2027)
7.8 Russia Market Size Analysis
7.8.1 Russia Antibodies in Oncology Market Size (2016-2027)
7.8.2 Russia Antibodies in Oncology Market Size by Type (2016-2027)
7.8.3 Russia Antibodies in Oncology Market Size by Application (2016-2027)

8 Asia-Pacific
8.1 Asia-Pacific Antibodies in Oncology Market Size (2016-2027)
8.2 Key Antibodies in Oncology Players Market Share in Asia-Pacific (2020-2021)
8.3 Asia-Pacific Antibodies in Oncology Market Size by Region
8.3.1 Asia-Pacific Antibodies in Oncology Market Size by Region (2016-2021)
8.3.2 Asia-Pacific Antibodies in Oncology Market Size Forecast by Region (2022-2027)
8.4 China Market Size Analysis
8.4.1 China Antibodies in Oncology Market Size (2016-2027)
8.4.2 China Antibodies in Oncology Market Size by Type (2016-2027)
8.4.3 China Antibodies in Oncology Market Size by Application (2016-2027)
8.5 Japan Market Size Analysis
8.5.1 Japan Antibodies in Oncology Market Size (2016-2027)
8.5.2 Japan Antibodies in Oncology Market Size by Type (2016-2027)
8.5.3 Japan Antibodies in Oncology Market Size by Application (2016-2027)
8.6 South Korea Market Size Analysis
8.6.1 South Korea Antibodies in Oncology Market Size (2016-2027)
8.6.2 South Korea Antibodies in Oncology Market Size by Type (2016-2027)
8.6.3 South Korea Antibodies in Oncology Market Size by Application (2016-2027)
8.7 India Market Size Analysis
8.7.1 India Antibodies in Oncology Market Size (2016-2027)
8.7.2 India Antibodies in Oncology Market Size by Type (2016-2027)
8.7.3 India Antibodies in Oncology Market Size by Application (2016-2027)
8.8 Australia Market Size Analysis
8.8.1 Australia Antibodies in Oncology Market Size (2016-2027)
8.8.2 Australia Antibodies in Oncology Market Size by Type (2016-2027)
8.8.3 Australia Antibodies in Oncology Market Size by Application (2016-2027)
8.9 Taiwan Market Size Analysis
8.9.1 Taiwan Antibodies in Oncology Market Size (2016-2027)
8.9.2 Taiwan Antibodies in Oncology Market Size by Type (2016-2027)
8.9.3 Taiwan Antibodies in Oncology Market Size by Application (2016-2027)
8.10 Indonesia Market Size Analysis
8.10.1 Indonesia Antibodies in Oncology Market Size (2016-2027)
8.10.2 Indonesia Antibodies in Oncology Market Size by Type (2016-2027)
8.10.3 Indonesia Antibodies in Oncology Market Size by Application (2016-2027)
8.11 Thailand Market Size Analysis
8.11.1 Thailand Antibodies in Oncology Market Size (2016-2027)
8.11.2 Thailand Antibodies in Oncology Market Size by Type (2016-2027)
8.11.3 Thailand Antibodies in Oncology Market Size by Application (2016-2027)
8.12 Malaysia Market Size Analysis
8.12.1 Malaysia Antibodies in Oncology Market Size (2016-2027)
8.12.2 Malaysia Antibodies in Oncology Market Size by Type (2016-2027)
8.12.3 Malaysia Antibodies in Oncology Market Size by Application (2016-2027)
8.13 Philippines Market Size Analysis
8.13.1 Philippines Antibodies in Oncology Market Size (2016-2027)
8.13.2 Philippines Antibodies in Oncology Market Size by Type (2016-2027)
8.13.3 Philippines Antibodies in Oncology Market Size by Application (2016-2027)
8.14 Vietnam Market Size Analysis
8.14.1 Vietnam Antibodies in Oncology Market Size (2016-2027)
8.14.2 Vietnam Antibodies in Oncology Market Size by Type (2016-2027)
8.14.3 Vietnam Antibodies in Oncology Market Size by Application (2016-2027)

9 Latin America
9.1 Latin America Antibodies in Oncology Market Size (2016-2027)
9.2 Key Antibodies in Oncology Players Market Share in Latin America (2020-2021)
9.3 Latin America Antibodies in Oncology Market Size by Country
9.3.1 Latin America Antibodies in Oncology Market Size by Country (2016-2021)
9.3.2 Latin America Antibodies in Oncology Market Size Forecast by Country (2022-2027)
9.4 Mexico Market Size Analysis
9.4.1 Mexico Antibodies in Oncology Market Size (2016-2027)
9.4.2 Mexico Antibodies in Oncology Market Size by Type (2016-2027)
9.4.3 Mexico Antibodies in Oncology Market Size by Application (2016-2027)
9.5 Brazil Market Size Analysis
9.5.1 Brazil Antibodies in Oncology Market Size (2016-2027)
9.5.2 Brazil Antibodies in Oncology Market Size by Type (2016-2027)
9.5.3 Brazil Antibodies in Oncology Market Size by Application (2016-2027)
9.6 Argentina Market Size Analysis
9.6.1 Argentina Antibodies in Oncology Market Size (2016-2027)
9.6.2 Argentina Antibodies in Oncology Market Size by Type (2016-2027)
9.6.3 Argentina Antibodies in Oncology Market Size by Application (2016-2027)

10 Middle East & Africa
10.1 Middle East & Africa Antibodies in Oncology Market Size (2016-2027)
10.2 Key Antibodies in Oncology Players Market Share in Middle East & Africa (2020-2021)
10.3 Middle East & Africa Antibodies in Oncology Market Size by Country
10.3.1 Middle East & Africa Antibodies in Oncology Market Size by Country (2016-2021)
10.3.2 Middle East & Africa Antibodies in Oncology Market Size Forecast by Country (2022-2027)
10.4 Turkey Market Size Analysis
10.4.1 Turkey Antibodies in Oncology Market Size (2016-2027)
10.4.2 Turkey Antibodies in Oncology Market Size by Type (2016-2027)
10.4.3 Turkey Antibodies in Oncology Market Size by Application (2016-2027)
10.5 Saudi Arabia Market Size Analysis
10.5.1 Saudi Arabia Antibodies in Oncology Market Size (2016-2027)
10.5.2 Saudi Arabia Antibodies in Oncology Market Size by Type (2016-2027)
10.5.3 Saudi Arabia Antibodies in Oncology Market Size by Application (2016-2027)
10.6 UAE Market Size Analysis
10.6.1 UAE Antibodies in Oncology Market Size (2016-2027)
10.6.2 UAE Antibodies in Oncology Market Size by Type (2016-2027)
10.6.3 UAE Antibodies in Oncology Market Size by Application (2016-2027)

11 Key Players Profiles
11.1 Novartis International AG
11.1.1 Novartis International AG Company Details
11.1.2 Novartis International AG Business Overview and Its Total Revenue
11.1.3 Novartis International AG Antibodies in Oncology Introduction
11.1.4 Novartis International AG Revenue in Antibodies in Oncology Business (2016-2021)
11.1.5 Novartis International AG Recent Development
11.2 GlaxoSmithKline plc
11.2.1 GlaxoSmithKline plc Company Details
11.2.2 GlaxoSmithKline plc Business Overview and Its Total Revenue
11.2.3 GlaxoSmithKline plc Antibodies in Oncology Introduction
11.2.4 GlaxoSmithKline plc Revenue in Antibodies in Oncology Business (2016-2021)
11.2.5 GlaxoSmithKline plc Recent Development
11.3 Biogen Idec Inc.
11.3.1 Biogen Idec Inc. Company Details
11.3.2 Biogen Idec Inc. Business Overview and Its Total Revenue
11.3.3 Biogen Idec Inc. Antibodies in Oncology Introduction
11.3.4 Biogen Idec Inc. Revenue in Antibodies in Oncology Business (2016-2021)
11.3.5 Biogen Idec Inc. Recent Development
11.4 Bristol Myers Squibb Co.
11.4.1 Bristol Myers Squibb Co. Company Details
11.4.2 Bristol Myers Squibb Co. Business Overview and Its Total Revenue
11.4.3 Bristol Myers Squibb Co. Antibodies in Oncology Introduction
11.4.4 Bristol Myers Squibb Co. Revenue in Antibodies in Oncology Business (2016-2021)
11.4.5 Bristol Myers Squibb Co. Recent Development
11.5 AstraZeneca plc.
11.5.1 AstraZeneca plc. Company Details
11.5.2 AstraZeneca plc. Business Overview and Its Total Revenue
11.5.3 AstraZeneca plc. Antibodies in Oncology Introduction
11.5.4 AstraZeneca plc. Revenue in Antibodies in Oncology Business (2016-2021)
11.5.5 AstraZeneca plc. Recent Development
11.6 Celltrion
11.6.1 Celltrion Company Details
11.6.2 Celltrion Business Overview and Its Total Revenue
11.6.3 Celltrion Antibodies in Oncology Introduction
11.6.4 Celltrion Revenue in Antibodies in Oncology Business (2016-2021)
11.6.5 Celltrion Recent Development
11.7 3SBIO
11.7.1 3SBIO Company Details
11.7.2 3SBIO Business Overview and Its Total Revenue
11.7.3 3SBIO Antibodies in Oncology Introduction
11.7.4 3SBIO Revenue in Antibodies in Oncology Business (2016-2021)
11.7.5 3SBIO Recent Development
11.8 Celgen Biopharma
11.8.1 Celgen Biopharma Company Details
11.8.2 Celgen Biopharma Business Overview and Its Total Revenue
11.8.3 Celgen Biopharma Antibodies in Oncology Introduction
11.8.4 Celgen Biopharma Revenue in Antibodies in Oncology Business (2016-2021)
11.8.5 Celgen Biopharma Recent Development
11.9 Dr Reddy’s
11.9.1 Dr Reddy’s Company Details
11.9.2 Dr Reddy’s Business Overview and Its Total Revenue
11.9.3 Dr Reddy’s Antibodies in Oncology Introduction
11.9.4 Dr Reddy’s Revenue in Antibodies in Oncology Business (2016-2021)
11.9.5 Dr Reddy’s Recent Development

12 Analyst's Viewpoints/Conclusion

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details